Which has stronger valuation and earnings, SVRA or ELDN?

Savara is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Savara N/A N/A -$118.84M -$0.58 N/A Eledon Pharmaceuticals N/A N/A -$45.62M -$0.91 N/A

Is SVRA or ELDN more profitable?

Savara's return on equity of -90.28% beat Eledon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Savara N/A -90.28% -68.95% Eledon Pharmaceuticals N/A -149.63% -50.84%

Does the media prefer SVRA or ELDN?

In the previous week, Savara and Savara both had 2 articles in the media. Eledon Pharmaceuticals' average media sentiment score of 1.35 beat Savara's score of -0.60 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Savara 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Eledon Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ELDN or KURA?

In the previous week, Kura Oncology had 14 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 16 mentions for Kura Oncology and 2 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 1.35 beat Kura Oncology's score of 0.79 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eledon Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kura Oncology 7 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, SANA or ELDN?

Sana Biotechnology is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sana Biotechnology N/A N/A -$244.17M -$0.76 N/A Eledon Pharmaceuticals N/A N/A -$45.62M -$0.91 N/A

Is SANA or ELDN more profitable?

Sana Biotechnology's return on equity of -103.02% beat Eledon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Sana Biotechnology N/A -103.02% -39.16% Eledon Pharmaceuticals N/A -149.63% -50.84%

Does the media favor SANA or ELDN?

In the previous week, Sana Biotechnology had 3 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 5 mentions for Sana Biotechnology and 2 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 1.35 beat Sana Biotechnology's score of 0.56 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sana Biotechnology 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eledon Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LXRX or ELDN?

In the previous week, Lexicon Pharmaceuticals and Lexicon Pharmaceuticals both had 2 articles in the media. Eledon Pharmaceuticals' average media sentiment score of 1.35 beat Lexicon Pharmaceuticals' score of 0.37 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexicon Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Eledon Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, FBRX or ELDN?

Forte Biosciences is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Forte Biosciences N/A N/A -$69.38M -$4.65 N/A Eledon Pharmaceuticals N/A N/A -$45.62M -$0.91 N/A

Is FBRX or ELDN more profitable?

Forte Biosciences' return on equity of -94.82% beat Eledon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Forte Biosciences N/A -94.82% -77.68% Eledon Pharmaceuticals N/A -149.63% -50.84%

Does the media refer more to FBRX or ELDN?

In the previous week, Forte Biosciences had 1 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 3 mentions for Forte Biosciences and 2 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 1.35 beat Forte Biosciences' score of 0.38 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Forte Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Eledon Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Eledon Pharmaceuticals (ELDN) Competitors

$3.45 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Compare

ELDN vs. SVRA, KURA, SANA, LXRX, and FBRX

Should you buy Eledon Pharmaceuticals stock or one of its competitors? Eledon Pharmaceuticals's main competitors and comparable companies include Savara (SVRA), Kura Oncology (KURA), Sana Biotechnology (SANA), Lexicon Pharmaceuticals (LXRX), and Forte Biosciences (FBRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Eledon Pharmaceuticals compare to Savara?

Savara (NASDAQ:SVRA) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

Savara is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.58	N/A
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.91	N/A

Savara has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market. Comparatively, Eledon Pharmaceuticals has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market.

87.9% of Savara shares are owned by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. 5.3% of Savara shares are owned by insiders. Comparatively, 9.6% of Eledon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Savara and Savara both had 2 articles in the media. Eledon Pharmaceuticals' average media sentiment score of 1.35 beat Savara's score of -0.60 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Eledon Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Savara presently has a consensus target price of $10.14, suggesting a potential upside of 81.45%. Eledon Pharmaceuticals has a consensus target price of $9.67, suggesting a potential upside of 180.19%. Given Eledon Pharmaceuticals' higher possible upside, analysts clearly believe Eledon Pharmaceuticals is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Eledon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Savara's return on equity of -90.28% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-90.28%	-68.95%
Eledon Pharmaceuticals	N/A	-149.63%	-50.84%

Summary

Eledon Pharmaceuticals beats Savara on 7 of the 13 factors compared between the two stocks.

How does Eledon Pharmaceuticals compare to Kura Oncology?

Eledon Pharmaceuticals (NASDAQ:ELDN) and Kura Oncology (NASDAQ:KURA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.

Eledon Pharmaceuticals presently has a consensus price target of $9.67, suggesting a potential upside of 180.19%. Kura Oncology has a consensus price target of $25.40, suggesting a potential upside of 113.62%. Given Eledon Pharmaceuticals' higher probable upside, equities analysts plainly believe Eledon Pharmaceuticals is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

In the previous week, Kura Oncology had 14 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 16 mentions for Kura Oncology and 2 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 1.35 beat Kura Oncology's score of 0.79 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eledon Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kura Oncology	7 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eledon Pharmaceuticals has a net margin of 0.00% compared to Kura Oncology's net margin of -384.30%. Eledon Pharmaceuticals' return on equity of -149.63% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-149.63%	-50.84%
Kura Oncology	-384.30%	-207.18%	-45.17%

Eledon Pharmaceuticals has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market.

56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. 9.6% of Eledon Pharmaceuticals shares are owned by insiders. Comparatively, 7.6% of Kura Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Eledon Pharmaceuticals has higher earnings, but lower revenue than Kura Oncology. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.91	N/A
Kura Oncology	$77.23M	13.70	-$278.67M	-$3.37	N/A

Summary

Eledon Pharmaceuticals beats Kura Oncology on 9 of the 15 factors compared between the two stocks.

How does Eledon Pharmaceuticals compare to Sana Biotechnology?

Sana Biotechnology (NASDAQ:SANA) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

Sana Biotechnology's return on equity of -103.02% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-103.02%	-39.16%
Eledon Pharmaceuticals	N/A	-149.63%	-50.84%

Sana Biotechnology is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.76	N/A
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.91	N/A

88.2% of Sana Biotechnology shares are owned by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. 25.4% of Sana Biotechnology shares are owned by company insiders. Comparatively, 9.6% of Eledon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Sana Biotechnology has a beta of 2.16, indicating that its share price is 116% more volatile than the broader market. Comparatively, Eledon Pharmaceuticals has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market.

Sana Biotechnology presently has a consensus target price of $9.33, indicating a potential upside of 138.70%. Eledon Pharmaceuticals has a consensus target price of $9.67, indicating a potential upside of 180.19%. Given Eledon Pharmaceuticals' higher probable upside, analysts plainly believe Eledon Pharmaceuticals is more favorable than Sana Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Eledon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Sana Biotechnology had 3 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 5 mentions for Sana Biotechnology and 2 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 1.35 beat Sana Biotechnology's score of 0.56 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sana Biotechnology	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eledon Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Sana Biotechnology beats Eledon Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Eledon Pharmaceuticals compare to Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

In the previous week, Lexicon Pharmaceuticals and Lexicon Pharmaceuticals both had 2 articles in the media. Eledon Pharmaceuticals' average media sentiment score of 1.35 beat Lexicon Pharmaceuticals' score of 0.37 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexicon Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eledon Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lexicon Pharmaceuticals has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market. Comparatively, Eledon Pharmaceuticals has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market.

Eledon Pharmaceuticals has lower revenue, but higher earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals	$49.80M	20.55	-$50.34M	-$0.15	N/A
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.91	N/A

Eledon Pharmaceuticals has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -147.38%. Lexicon Pharmaceuticals' return on equity of -37.53% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals	-147.38%	-37.53%	-24.96%
Eledon Pharmaceuticals	N/A	-149.63%	-50.84%

74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are held by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are held by company insiders. Comparatively, 9.6% of Eledon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Lexicon Pharmaceuticals presently has a consensus target price of $4.55, indicating a potential upside of 97.83%. Eledon Pharmaceuticals has a consensus target price of $9.67, indicating a potential upside of 180.19%. Given Eledon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Eledon Pharmaceuticals is more favorable than Lexicon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexicon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Eledon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Lexicon Pharmaceuticals and Eledon Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Eledon Pharmaceuticals compare to Forte Biosciences?

Forte Biosciences (NASDAQ:FBRX) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

Forte Biosciences' return on equity of -94.82% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-94.82%	-77.68%
Eledon Pharmaceuticals	N/A	-149.63%	-50.84%

Forte Biosciences has a beta of 2.6, suggesting that its stock price is 160% more volatile than the broader market. Comparatively, Eledon Pharmaceuticals has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market.

Forte Biosciences presently has a consensus price target of $71.67, indicating a potential downside of 6.83%. Eledon Pharmaceuticals has a consensus price target of $9.67, indicating a potential upside of 180.19%. Given Eledon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eledon Pharmaceuticals is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Eledon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Forte Biosciences is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38M	-$4.65	N/A
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.91	N/A

In the previous week, Forte Biosciences had 1 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 3 mentions for Forte Biosciences and 2 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 1.35 beat Forte Biosciences' score of 0.38 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Forte Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eledon Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

77.6% of Forte Biosciences shares are owned by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. 4.4% of Forte Biosciences shares are owned by company insiders. Comparatively, 9.6% of Eledon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Eledon Pharmaceuticals beats Forte Biosciences on 9 of the 13 factors compared between the two stocks.

Get Eledon Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELDN vs. The Competition

Export

Metric	Eledon Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$280.35M	$4.00B	$7.32B	$12.82B
Dividend Yield	N/A	3.64%	2.54%	10.79%
P/E Ratio	-3.79	11.68	272.91	24.33
Price / Sales	N/A	1,240.56	594.70	76.14
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	2.56	17.36	11.26	6.42
Net Income	-$45.62M	-$22.72M	$3.47B	$348.89M
7 Day Performance	-3.63%	2.76%	2.19%	0.51%
1 Month Performance	-3.63%	9.66%	7.62%	4.84%
1 Year Performance	32.69%	54.97%	25.17%	17.04%

Eledon Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELDN Eledon Pharmaceuticals	2.2535 of 5 stars	$3.45 flat	$9.67 +180.2%	+32.7%	$280.35M	N/A	N/A	10	News Coverage Analyst Downgrade
SVRA Savara	1.8125 of 5 stars	$5.37 flat	$10.14 +88.9%	+76.9%	$1.10B	N/A	N/A	20
KURA Kura Oncology	3.1516 of 5 stars	$12.33 +9.3%	$25.62 +107.7%	+55.4%	$1.09B	$77.23M	N/A	130	Insider Trade High Trading Volume
SANA Sana Biotechnology	2.1945 of 5 stars	$3.63 -1.4%	$9.33 +157.1%	+9.2%	$1.09B	N/A	N/A	380	Gap Down
LXRX Lexicon Pharmaceuticals	1.4397 of 5 stars	$2.41 +3.0%	$4.55 +88.8%	+93.3%	$1.07B	$49.80M	N/A	140

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELDN) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eledon Pharmaceuticals (ELDN) Competitors

ELDN vs. SVRA, KURA, SANA, LXRX, and FBRX

How does Eledon Pharmaceuticals compare to Savara?

Summary

How does Eledon Pharmaceuticals compare to Kura Oncology?

Summary

How does Eledon Pharmaceuticals compare to Sana Biotechnology?

Summary

How does Eledon Pharmaceuticals compare to Lexicon Pharmaceuticals?

Summary

How does Eledon Pharmaceuticals compare to Forte Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELDN vs. The Competition

Eledon Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eledon Pharmaceuticals (ELDN) Competitors

ELDN vs. SVRA, KURA, SANA, LXRX, and FBRX

How does Eledon Pharmaceuticals compare to Savara?

Which has stronger valuation and earnings, SVRA or ELDN?

Which has more risk & volatility, SVRA or ELDN?

Do insiders and institutionals hold more shares of SVRA or ELDN?

Does the media prefer SVRA or ELDN?

Do analysts rate SVRA or ELDN?

Is SVRA or ELDN more profitable?

Summary

How does Eledon Pharmaceuticals compare to Kura Oncology?

Do analysts rate ELDN or KURA?

Does the media favor ELDN or KURA?

Is ELDN or KURA more profitable?

Which has more volatility & risk, ELDN or KURA?

Do insiders & institutionals have more ownership in ELDN or KURA?

Which has preferable earnings & valuation, ELDN or KURA?

Summary

How does Eledon Pharmaceuticals compare to Sana Biotechnology?

Is SANA or ELDN more profitable?

Which has preferable earnings and valuation, SANA or ELDN?

Do institutionals and insiders have more ownership in SANA or ELDN?

Which has more volatility & risk, SANA or ELDN?

Do analysts recommend SANA or ELDN?

Does the media favor SANA or ELDN?

Summary

How does Eledon Pharmaceuticals compare to Lexicon Pharmaceuticals?

Does the media prefer LXRX or ELDN?

Which has more risk & volatility, LXRX or ELDN?

Which has preferable valuation and earnings, LXRX or ELDN?

Is LXRX or ELDN more profitable?

Do insiders and institutionals believe in LXRX or ELDN?

Do analysts prefer LXRX or ELDN?

Summary

How does Eledon Pharmaceuticals compare to Forte Biosciences?

Is FBRX or ELDN more profitable?

Which has more risk and volatility, FBRX or ELDN?

Do analysts prefer FBRX or ELDN?

Which has preferable earnings & valuation, FBRX or ELDN?

Does the media refer more to FBRX or ELDN?

Do insiders & institutionals hold more shares of FBRX or ELDN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELDN vs. The Competition

Eledon Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools